Hanson D, Winterbauer R H, Kirtland S H, Wu R
Section of Pulmonary and Critical Care Medicine, Virginia Mason Medical Center, Seattle, WA 98111, USA.
Chest. 1995 Aug;108(2):305-10. doi: 10.1378/chest.108.2.305.
The study group consisted of 58 patients with idiopathic pulmonary fibrosis (IPF) recognized between 1970 and 1991 who were treated for their pulmonary disease, survived for at least 1 year from the time of initiation of treatment, and had forced vital capacity (FVC) measurements at the time of diagnosis and 9 to 15 months later. Forty-four of the patients also had a single-breath diffusing capacity (Dsb) measured initially and after 9 to 15 months of treatment and 33 patients had an arterial blood gas, breathing room air at the time of diagnosis and 9 to 15 months into therapy. Patients' conditions were classified as improved, unchanged, or worse after the year of treatment based on each of the three pulmonary function tests. A > or = 10% increase in FVC, > or = 20% increase in Dsb, and > or = 5 mm Hg decrease in alveolar-arterial difference in oxygen partial pressure [P(A-a)O2] defined improved function. A > or = 10% decrease in FVC, > or = 20% decrease in Dsb, and > or = 5 mm Hg increase in P(A-a)O2 defined worse function. Patients with < 10% change in FVC, < 20% change in Dsb, and < 5 mm Hg change in P(A-a)O2 were regarded as having unchanged conditions. Kaplan-Meier survival plots and the Cox proportional hazard regression model were used to analyze survival time in relation to change in pulmonary function after 1 year of therapy. Patients with an improved or unchanged FVC at 1 year had no difference in survival (p = 0.75), but both showed enhanced survival compared with patients with a > or = 10% reduction in FVC with 1 year of treatment (p < 0.001). Patients with an improved or unchanged Dsb at 1 year also had no difference in survival (p = 0.21) but again, both showed enhanced survival compared with patients with > or = 20% decrease in Dsb with 1 year of treatment (p < 0.001). Changes in gas exchange after 1 year of treatment did not correlate with survival in the three groups. There was a trend for longer survival in improved patients compared with those with worsening gas exchange, but the p value was not significant at 0.17. We conclude that changes in the FVC and Dsb after 1 year of treatment are strongly predictive of duration of survival in patients with IPF.
研究组由1970年至1991年间确诊的58例特发性肺纤维化(IPF)患者组成,这些患者接受了肺部疾病治疗,从治疗开始起存活至少1年,且在诊断时及9至15个月后进行了用力肺活量(FVC)测量。44例患者在治疗初始及9至15个月后还进行了单次呼吸弥散量(Dsb)测量,33例患者在诊断时及治疗9至15个月时进行了动脉血气分析,均为呼吸室内空气状态下。根据三项肺功能测试中的每一项,将患者在治疗一年后的病情分为改善、不变或恶化。FVC增加≥10%、Dsb增加≥20%以及肺泡-动脉氧分压差[P(A-a)O2]降低≥5 mmHg定义为功能改善。FVC降低≥10%、Dsb降低≥20%以及P(A-a)O2增加≥5 mmHg定义为功能恶化。FVC变化<10%、Dsb变化<20%以及P(A-a)O2变化<5 mmHg的患者被视为病情未变。采用Kaplan-Meier生存曲线和Cox比例风险回归模型分析治疗1年后生存时间与肺功能变化的关系。治疗1年后FVC改善或未变的患者生存情况无差异(p = 0.75),但与治疗1年后FVC降低≥10%的患者相比,二者的生存率均有所提高(p < 0.001)。治疗1年后Dsb改善或未变的患者生存情况也无差异(p = 0.21),同样,与治疗1年后Dsb降低≥20%的患者相比,二者的生存率均有所提高(p < 0.001)。治疗1年后气体交换的变化与三组患者的生存情况无关。改善的患者与气体交换恶化的患者相比,有生存时间更长的趋势,但p值为0.17,无统计学意义。我们得出结论,治疗1年后FVC和Dsb的变化可强烈预测IPF患者的生存时长。